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Photodynamic therapy (PDT) utilizing Photofrin is proving to be effective for the treat-
ment of early stage lung cancers. The effect of PDT utilizing YAG-OPO laser as new
light source was evaluated in 26 patients (29 lesions) with early stage lung cancers. YAG-
OPO laser is solid state tunable laser which is easy to change wavelength between 620 and
670nm exciting various kinds of photosensitizers. Moreover, YAG-OPO laser is more re-
liable, smaller and has less consumables than argon-dye laser or excimer-dye laser. As
the result ofPDT with YAG-OPO laser, complete remission (CR) was obtained in 82.6%
of the 29 lesions, partial remission (PR) in 13.8% and no change (NC) was obtained in
3.4%. We conclude that PDT utilizing YAG-OPO laser is efficacious in the treatment
of early stage lung cancers and can achieve complete remission.
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INTRODUCTION
Increasing numbers of early stage lung cancer
cases are being detected as a result of improved
survey and diagnostic techniques. Despite the pos-
sibility of curative resection in many such cases,
many of the patients are frequently at high surgical
risk because of coexisting chronic obstructive
pulmonary disease or cardiovascular disease. Con-
sidering the quality of life of the patients, it is es-
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sential to preserve lung tissue by treating the initial
early stage lung cancer as conservatively as pos-
sible. The introduction of photodynamic therapy
(PDT) has provided a new therapeutic alternative
to surgery. PDT is a new cancer treatment mo-
dality that selectively destroys cancer cells by an
interaction between absorbed light and a retained
photosensitizer [1,2].
Since PDT with Photofrin and excimer-dye
laser received approval from the Ministry ofHealth76 H. KATO et al.
and Welfare of Japan in October 1994, increasing
attention has been focused on this new treatment
technique. Moreover, new photosensitizers of the
second and the third generation have been devel-
oped, and tunable lasers are expected to apply for
new generation photosensitizer [3].
This paper evaluates the YAG-OPO laser as
a new light source for PDT in early stage lung
cancer.
PATIENTS AND METHODS
Patient Eligibility
Eligibility criteria were as follows: (1) histologi-
cally and cytologically proven early stage lung
cancer; no metastasis in hilar or mediastinal lymph
nodes and no distant metastasis (stage 0:TisNOM0
or stage I: T1NOM0); (2) performance status (PS)
of 0 to 2; (3) arterial oxygen pressure tension
(PaO2) greater than 60 Torr; (4) no tumor shadow
on chest X-ray; (5) endoscopically visible distal
tumor margins and accessibility to laser irradia-
tion; (6) no previous treatment. Informed consent
was obtained from all patients or their relatives.
Laser Equipment
The light source employed in this trial was the
YAG-OPO laser from Ishikawajima-Harima
Heavy Industries Co., Ltd. (IHI, Tokyo, Japan).
The YAG-OPO laser stands for an Optical Para-
metric Oscillator pumped by a Q-switched
Nd:YAG laser. The wavelength of Nd:YAG
laser (1,064 nm) is converted into a third (355 nm)
by two nonlinear crystals. The THG of Nd :YAG
laser (Third Harmonic Generation; 355 nm light:
Ap) pumps the OPO, which is composed of a reso-
nator and a nonlinear crystal, as a result two dif-
ferent beams are generated by nonlinear effects.
One beam is called the signal light (As), and the
other is the idler (Ai). Generally, As is shorter than
Ai and As is used as the irradiating beam. The com-
bination of As and Ai can be changed easily, ac-
cording to the angle of the OPO crystal. (Figs.
and 2). This system consists of a laser system, an
operating stand, a chiller and an optical fiber. The
laser emits a high peak power light beam between
620 and 670 nm. The beam can be irradiated onto
tumors by two types of optical fibers.
The specifications are as follows:
(1) wavelength: 620-670nm
(2) repetition rate: 25, 50 Hz
(3) Max. pulse energy: 6 mJ/pulse (output of opti-
cal fiber)
(4) Max. average power: 300mW (6mJ x 50 Hz)
(5) pulse width: 5-8 ns
(6) peak power: < MW
When the parameters are set at the operating
stand, the YAG-OPO laser system automatically
starts up and stands by. The parameters displayed
on the color LCD touched panel are repetition
rate, wavelength, pulse energy, total energy, type
of fiber tip (forward-expanded irradiating tip and
side irradiating tip) and remaining time. The repe-
tition rate, wavelength, pulse energy, total energy
and type of fiber tip can be changed easily on the
control panel. For reliability, the computer con-
trolling system stabilizes power and wavelength
and fiber calibration. Furthermore, the function of
photo-coagulation for YAG laser (Max. Power:
10W) is available as an option [4].
Procedure
Bronchoscopical PDT is performed with topical
anesthesia approximately 48 h after the intravenous
injection of 2.0mg/kg body weight of Photofrin.
After the injection of Photofrin, the patients are
instructed to avoid direct sunlight for at least four
weeks. The YAG-OPO laser emits a 630nm wave-
length beam which has the deepest tissue penetra-
tion among the wavelengths that excite Photofrin.
The laser beam is transmitted via a quartz fiber
(400mm) inserted through the instrumentation
channel of a fiberoptic bronchoscope.
The pulse energy of the output at the fiber tip
was adjusted to 4mJ/pulse. The frequency was
50 Hz, giving energy densities of 100 J/cm2. AfterPDT WITH YAG-OPO LASER 77
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FIGURE 2 The function of YAG-OPO laser system. A computer controls the total laser system, and the stable laser beam is
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the PDT procedure, bronchial toilet was performed
every 2 or 3 days for week.
Tumor response was classified into three grades:
complete remission (CR), when no tumor was ob-
servable by biopsy and/or brushing cytology for at
least 4 weeks; partial remission (PR) which is de-
fined as a reduction in tumor volume greater than
50% but with the cancer still recognizable on biopsy
or brushing for at least 4 weeks after therapy; and
no change (NC) which is defined as no change in
tumor size or a decrease of less than 50% and the
cancer still recognizable by biopsy or brushing.
One month after treatment, the tumor response to
PDT was evaluated endoscopically, roentgeno-
graphically, cytologically, and histologically.
RESULTS
TABLE Patients characteristics
No. of patients 26
Age (years)
Median 69.0
Range 53-79
Sex (male/female) 26/0
PS
0 19
7
No. of carcinoma 29
Tumor stage
0 (TisNOM0) 10
(T1NOM0) 19
Histlogy, squamous cell 29
Bronchoscopic appearance
Superficial type 16
Nodular 13
Tumor size
<0.5 10
0.5-0.9 12
0.9-1.9 6
2.0<
Patient Characteristics
From May 1995 through December 1996, 28
patients with 31 carcinomas were entered into this
study. However 2 patients with 2 carcinomas were
excluded, because of lesions lacking clear visibility
of the distal tumor margins. Twenty-six male
patients with 29 carcinomas were eligible for re-
sponse and side effect assessment. Characteristics
of the eligible patients are listed in Table I. The
age distribution ranges from 53 to 79 years old.
According to tumor staging, 10 carcinomas were
identified as stage 0 (TisNOM0) and 19 as stage I
(T1NOM0). Histologically, all cases were squa-
mous cell carcinoma. Twenty-two carcinomas had
a longitudinal tumor extent of smaller than cm
and 7 carcinomas had a longitudinal tumor extent
of greater than cm.
Response
Tumor response to PDT in 29 carcinomas is
shown in Table II. Table III shows the summary
of results of PDT. CR was obtained in 24 lesions
out of 29 lesions (82.6%), PR in 4 lesions and NC
in one lesion. According to tumor stage, of the 10
carcinomas identified as stage 0 (TisNOM0), CR
was obtained on 9 (90%) carcinomas and PR in 1.
Of the 19 carcinomas identified as stage I
(T1NOM0), 15 (78.9%) carcinomas have CR, 3
carcinomas have PR and carcinoma have NC.
Of the 9 CR cases, 2 recurred locally and were
then treated by PDT again, and CR was achieved.
One patient died with heart failure.
The therapeutic effectiveness of PDT was anal-
yzed according to the longitudinal tumor size.
The univariate analysis was based on 2 2 tables
and differences were tested by the 2 test. Of the
22 cancer lesions that had a longitudinal tumor
extent of cm or less, 19 (86.4%) obtained a CR
after initial PDT, however of the 7 carcinomas that
had a longitudinal tumor extent of greater that
cm, 6 (85.7%) showed CR after PDT. There was
no significant difference between the two groups.
Adverse Effect
There were no adverse effects related to the
YAG-OPO laser irradiation, although mild skin
photosensitivity caused by Photofrin was seen in
4 patients.PDT WITH YAG-OPO LASER 79
TABLE II Response of PDT with YAG-OPO laser
No. Age Sex Location Tumor size Histologic Clinical Bronchoscopic Response Recurrence
mm mm type stage appearance
79 M bif*. of left upper & lower
bronchi
2 56 M left B
3 68 M right B
left B +
4 67 M right B3-B
2
5 79 M right B +
6 72 M right B1-B
7 70 M right B
8 71 M trachea
9 71 M right B1
10 71 M left B +
11 65 M bif. of left upper & linguar
bronchi orifice of left B
12 74 M left B
13 71 M right B
14 75 M left B
15 66 M left B
16 67 M right B + 3-2
17 65 M left B3a
18 76 M rightB
19 70 M bif. of left upper & lower
bronchi
20 65 M orifice of left upper lobe
bronchi
orifice of right upper lobe
bronchi
21 72 M trachea
22 72 M left B
23 53 M left B1 +
left B
1
24 66 M left B3-B
4
25 64 M left B
26 68 M left B
3 3 Sq* nodular CR
2 3 Sq superficial CR
15 15 Sq nodular CR
3 3 Sq nodular CR
5 3 Sq 0 superficial CR
15 15 Sq nodular CR
5 x 5 Sq superficial CR
Sq superficial CR
2 3 Sq nodular CR
5 5 Sq superficial PR
5 5 Sq 0 superficial PR
15.7 20 Sq 0 superficial CR
5 3 Sq superficial CR
4 3 Sq nodular CR
7 3 Sq superficial CR
5 4 Sq 0 nodular CR
10 7 Sq 0 superficial CR
3 x 3 Sq nodular CR
3 3 Sq 0 superficial CR
3 3 Sq superficial CR
3 3 Sq 0 superficial CR
7 7 Sq 0 superficial CR
10 10 Sq nodular PR
3 6 Sq nodular PR
3 5 Sq nodular NC
12 5 Sq nodular CR
5 4 Sq superficial CR
10 6 Sq 0 superficial CR
5 5 Sq 0 nodular CR
Sq*: squamous cell carcinoma; bif*: bifurcation.
Case Report
The case no. 5, 79-year-old man, squamous cell
carcinoma of the lung was initially diagnosed based
on positive sputum cytology. The tumors were
nodular, located in the right B + 2. The size of the
tumor is 15mm by 15mm in size. Since the
patient’s pulmonary function was very poor, he
was subsequently treated by PDT. Figure 3 shows
the tumor in the right B + 2, before and 2 months
after PDT. He is now apparently disease-free 17
months after PDT.
DISCUSSION
Photodynamic therapy, a relatively new modality
used in the treatment of cancer, has gained con-
siderable acceptance in the past decade. A wide
variety of malignancies have been treated by this
method and according to the literature, over 3000
patients worldwide have been treated with photo-
dynamic therapy [5]. The estimate of the number
of institutions and investigators involved with
PDT worldwide is about 90 and 180, respectively.
In Japan, PDT with Photofrin and excimer dye80 H. KATO et al.
TABLE III Summary of response
No. of Response Recurrence
Carcinomas
CR PR NC
Overall 29 24 (82.6%) 4 (13.8%) (3.4%) 2 (6.9%)
Tumor stage
0 (TisNOM0) 10 9 (90%) 0 0
(T1NOM0) 19 15 (78.9%) 3 2
Bronchoscopic appearance
Superficial type 16 15 (93.8%) 0
Nodular 13 10 (76.9%) 2 2
Tumor size
<0.5 lO lO (lOO%) o o o
0.5-0.9 12 9 (75.0%) 2
0.9-1.9 6 5 (83.3%) 0 2
2.0 __< (100%) 0 0 0
a b
FIGURE 3 Endoscopical findings of case no. 5, 79-year-old man, squamous cell carcinoma of the lung. The tumors were nodu-
lar, located in the right B+2. The size of the tumor 15 15mm in size (left) and bronchoscopic finding of same site 2 months
after PDT.
laser obtained government approval in October
1994 and finally obtained national insurance re-
imbursement status in April 1996 [3].
As the cost of medical care is one of the impor-
tant problems, we evaluated the cost-effectiveness
of PDT in early stage lung cancer cases against
lobectomy. Effectiveness was determined using
quality adjusted life years saved (QALYs) which
is the 5-year survival rate adjusted in terms of the
quality of life of the patient, and cost-effective-
ness rate was obtained based on the costs of treat-
ment methods during patient’s stay in the hospital.
Health care costs, including drugs, were calcu-
lated according to the 1993 National Health Insur-
ance list. The total cost of the operated group is
$14,948 and that for the PDT group is $8,475.PDT WITH YAG-OPO LASER 81
The cost-effectiveness rate of the operated group,
that is the average cost of treatment per post-
operative living month, was $313, while that of the
entire PDT group was $250. This indicates that
the cost-effectiveness rate for the operated group
was apparently 1.3 times higher than that of the
PDT group. The monthly cost-effectiveness rate
for the PDT group of superficial lesions smaller
than 2cm was $213 in which the cost was cheaper
in the PDT group [6].
The excimer-dye laser consists of a gas and dye
laser, which means that the system is large and
the maintenance cost is high. Therefore, a small
solid state laser would be useful for PDT. Since
the YAG-OPO laser is all solid state laser except
for the flash lamps, it is more reliable, smaller and
has less consumables than argon-dye laser or ex-
cimer-dye laser [4]. Moreover, the tunability of its
wavelength enables it to be used with various
kinds of photosensitizers; hematoporphyrin deri-
vative (630 nm), 5-ALA (630 nm), pheophorbide-a
(650nm), mono-L-aspartyl chlorin e6 (664nm),
aluminum phthalocyanine (670 nm), etc [7].
In a multi-center research study in Japan on
early stage lung cancer treated by PDT with
Photfrin and excimer-dye laser involving 66 carci-
nomas, CR was achieved in 51 carcinomas (77.3%)
after the initial PDT [8,9]. Our results with the
YAG-OPO laser were by no means inferior to
those data and also there was no serious adverse
effect by the laser itself except slight skin photo-
sensitivity which was caused by Photofrin. These
data encourage the future clinical use of the
YAG-OPO laser.
We previously reported that complete remission
was difficult to obtain in lesions which were
anatomically difficult to photoirradiate. However,
the side irradiating tip made it possible to photo-
radiate from an angle of 90 to the surface of the
lesion in this study.
PDT holds great future potential in the curative
treatment ofearly stage cancer, palliative treatment
of advanced cancer for local improvement of
lesions, combination therapy with surgery and with
ionizing radiation and chemotherapy. QOL can
be maintained by PDT especially in the elderly
and patients with multiple lung cancers. PDT is
cost-effective in comparison with other treatments.
When new photosensitizers which distribute more
equally in the tumor tissue which yields deeper
tissue penetration due to its longer wavelength are
used clinically, more successful results will be
obtained with YAG-OPO laser.
Recent studies on photodynamic therapy started
just 25 years ago. Therefore there are still a num-
ber of unsolved problems. However it is clear that
PDT is one of the new therapeutic strategies for
early stage central type lung cancer.
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